ES2176233T3 - Deteccion diagnostica amplificada con ribozimas. - Google Patents

Deteccion diagnostica amplificada con ribozimas.

Info

Publication number
ES2176233T3
ES2176233T3 ES94903451T ES94903451T ES2176233T3 ES 2176233 T3 ES2176233 T3 ES 2176233T3 ES 94903451 T ES94903451 T ES 94903451T ES 94903451 T ES94903451 T ES 94903451T ES 2176233 T3 ES2176233 T3 ES 2176233T3
Authority
ES
Spain
Prior art keywords
objective
riboenzyme
molecula
materialization
united
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94903451T
Other languages
English (en)
Inventor
Andy Shih
Jeffrey M Bockman
Shaji T George
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Sirna Therapeutics Inc
Original Assignee
Yale University
Ribozyme Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Ribozyme Pharmaceuticals Inc filed Critical Yale University
Application granted granted Critical
Publication of ES2176233T3 publication Critical patent/ES2176233T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • C12Q1/6823Release of bound markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/12Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121Hammerhead
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3517Marker; Tag

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Road Signs Or Road Markings (AREA)
  • Amplifiers (AREA)
  • Dental Preparations (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Stereo-Broadcasting Methods (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBE UN SISTEMA PARA EL USO DE UNA RIBOENZIMA COMO HERRAMIENTA DE DIAGNOSTICO PARA DETECTAR LA PRESENCIA DE UN ACIDO NUCLEICO, PROTEINA, U OTRA MOLECULA, EN EL QUE LA FORMACION DE UNA RIBOENZIMA ACTIVA Y LA DIVISION DE UN INDICADOR ANALIZABLE DEPENDE DE LA PRESENCIA O AUSENCIA DE UNA MOLECULA OBJETIVO ESPECIFICA. EL COMPONENTE ESENCIAL ES UNA RIBOENZIMA QUE SE UNE ESPECIFICAMENTE PERO REVERSIBLEMENTE A UN OBJETIVO SELECCIONADO EN COMBINACION CON UN CO-OBJETIVO MARCADO, PREFERENTEMENTE INMOVILIZADO EN UNA ESTRUCTURA DE SOPORTE. CUANDO EL OBJETIVO Y EL CO-OBJETIVO ESTAN UNIDOS, LA RIBOENZIMA DIVIDE LA MARCA DEL CO-OBJETIVO, QUE ES ENTONCES CUANTIFICABLE. PUESTO QUE LA RIBOENZIMA ESTA UNIDA REVERSIBLEMENTE POR EL OBJETIVO Y EL COOBJETIVO, PUEDE REASOCIARSE CON UN CO-OBJETIVO ADICIONAL, DIVIDIENDO MAS MARCAS Y POR LO TANTO AMPLIFICANDO LA SEÑAL DE REACCION. EN UNA MATERIALIZACION, EL OBJETIVO ES UN ACIDO NUCLEICO QUE HIBRIDIZA CON SECUENCIAS COMPLEMENTARIAS QUE FORMAN PARTE DE LA RIBOENZIMA; EN UNA SEGUNDA MATERIALIZACION, EL OBJETIVO ES UNA PROTEINA U OTRA MACROMOLECULA QUE ESTA UNIDA POR INTERACCIONES CON UNA PORCION DE LA MOLECULA DE LA RIBOENZIMA. EN OTRA MATERIALIZACION, SE UTILIZA UNA RIBOENZIMA TERMOESTABLE, DE MODO QUE UNA RIBOENZIMA UNIDA DE FORMA INADECUADA SE DESESTABILICE Y QUEDE INACTIVA A ELEVADAS TEMPERATURAS. TAMBIEN SE PRESENTA UN METODO PARA AISLAR RIOBOENZIMAS REGULABLES. LAS RIBOENZIMAS REGULABLES SON UTILES EN EL METODO PARA DETECTAR LA PRESENCIA DE UNA MACROMOLECULA ESPECIFICA, O PUEDEN SER UTILIZADAS EN METODOS IN VITRO O IN VIVO, PARA LA INACTIVACION O LA ACTIVACION DE LA DIVISION DE LAS MOLECULAS DE RNA OBJETIVO.
ES94903451T 1992-12-04 1993-12-03 Deteccion diagnostica amplificada con ribozimas. Expired - Lifetime ES2176233T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98530892A 1992-12-04 1992-12-04

Publications (1)

Publication Number Publication Date
ES2176233T3 true ES2176233T3 (es) 2002-12-01

Family

ID=25531365

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94903451T Expired - Lifetime ES2176233T3 (es) 1992-12-04 1993-12-03 Deteccion diagnostica amplificada con ribozimas.

Country Status (8)

Country Link
US (1) US5589332A (es)
EP (2) EP1195442A3 (es)
JP (2) JP3595841B2 (es)
AT (1) ATE217347T1 (es)
AU (1) AU675482B2 (es)
DE (1) DE69331911T2 (es)
ES (1) ES2176233T3 (es)
WO (1) WO1994013833A1 (es)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125270A1 (en) * 2000-12-18 2003-07-03 Lawrence Blatt Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
WO2002081494A1 (en) * 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US5599704A (en) * 1992-08-26 1997-02-04 Ribozyme Pharmaceuticals, Inc. ErbB2/neu targeted ribozymes
WO1995003427A2 (en) * 1993-07-19 1995-02-02 Gen-Probe Incorporated Oligonucleotide screening assay
WO1995016788A1 (en) * 1993-12-17 1995-06-22 Cubicciotti Roger S Nucleotide-directed assembly of bimolecular and multimolecular drugs and devices
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5998193A (en) * 1994-06-24 1999-12-07 Gene Shears Pty., Ltd. Ribozymes with optimized hybridizing arms, stems, and loops, tRNA embedded ribozymes and compositions thereof
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
JPH11500917A (ja) * 1995-02-27 1999-01-26 インテリジェン・リミテッド 生体分子の検出
CN1183812A (zh) * 1995-02-27 1998-06-03 音坦里吉有限公司 生物分子的检测方法
US6214546B1 (en) 1995-02-27 2001-04-10 Intelligene Ltd. Detection of biomolecules
US20040142895A1 (en) * 1995-10-26 2004-07-22 Sirna Therapeutics, Inc. Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
US20040102389A1 (en) * 1995-10-26 2004-05-27 Ribozyme Pharmaceuticals, Inc. Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US7034009B2 (en) * 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US20040220128A1 (en) * 1995-10-26 2004-11-04 Sirna Therapeutics, Inc. Nucleic acid based modulation of female reproductive diseases and conditions
DK1634890T3 (da) * 1996-01-24 2009-03-09 Third Wave Tech Inc Invasiv klövning af nukleinsyrer
US5985557A (en) * 1996-01-24 1999-11-16 Third Wave Technologies, Inc. Invasive cleavage of nucleic acids
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
WO1997047768A1 (en) * 1996-06-10 1997-12-18 Fenggang Wang Method for randomly synthesizing biopolymers
DE69735684T2 (de) * 1996-08-26 2007-04-05 Genetico Ltd. Katalytische Nukleinsäure und deren medizinische Verwendung
CA2275541A1 (en) * 1996-12-19 1998-06-25 Yale University Bioreactive allosteric polynucleotides
US20030186909A1 (en) * 1997-01-27 2003-10-02 Ribozyme Pharmaceuticals, Inc. Nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
EP0972081B1 (en) 1997-04-01 2007-06-13 Solexa Ltd. Method of nucleic acid amplification
US6194149B1 (en) * 1998-03-03 2001-02-27 Third Wave Technologies, Inc. Target-dependent reactions using structure-bridging oligonucleotides
AU756301B2 (en) * 1997-08-20 2003-01-09 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6482932B1 (en) 1997-11-05 2002-11-19 Ribozyme Pharmaceuticals, Incorporated Nucleoside triphosphates and their incorporation into oligonucleotides
DE69933856D1 (de) 1998-02-13 2006-12-14 Koester Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
US6140055A (en) * 1998-03-05 2000-10-31 Johnson & Johnson Research Pty Limited Zymogenic nucleic acid detection methods and related kits
WO1999053031A2 (en) * 1998-04-08 1999-10-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Process for producing cell clone libraries
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
IL126732A0 (en) * 1998-10-23 1999-08-17 Intelligene Ltd Pro drug
IL126731A0 (en) * 1998-10-23 1999-08-17 Intelligene Ltd A method of detection
DE19915141C2 (de) * 1999-03-26 2002-11-21 Artus Ges Fuer Molekularbiolog Detektion von Nucleinsäure-Amplifikaten
IL130606A0 (en) * 1999-06-23 2000-06-01 Intelligene Ltd An array of nucleic acid sequence
IL132710A0 (en) * 1999-11-02 2001-03-19 Intelligene Ltd Catalytic nucleic acid sequences
WO2002094185A2 (en) 2001-05-18 2002-11-28 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
CA2398282A1 (en) * 2000-02-11 2001-08-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US20030065155A1 (en) * 2000-03-06 2003-04-03 Nassim Usman Nucleic acid sensor molecules
CA2400415A1 (en) * 2000-03-06 2001-09-13 Ribozyme Pharmaceuticals, Inc. Nucleic acid sensor molecules
US20040023292A1 (en) * 2001-10-19 2004-02-05 Mcswiggen James Method and reagent for the detection of proteins and peptides
US20040009510A1 (en) * 2000-03-06 2004-01-15 Scott Seiwert Allosteric nucleic acid sensor molecules
JP2004515219A (ja) * 2000-06-15 2004-05-27 ボード・オブ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム 調節可能な触媒活性な核酸
WO2001096541A2 (en) * 2000-06-15 2001-12-20 Board Of Regents Allosterically regulated ribozymes
US20080032942A1 (en) * 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20050209179A1 (en) * 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US7125660B2 (en) * 2000-09-13 2006-10-24 Archemix Corp. Nucleic acid sensor molecules and methods of using same
AR031640A1 (es) * 2000-12-08 2003-09-24 Applied Research Systems Amplificacion isotermica de acidos nucleicos en un soporte solido
US20050182009A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050164224A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US20050187174A1 (en) * 2001-05-18 2005-08-25 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20050159376A1 (en) * 2002-02-20 2005-07-21 Slrna Therapeutics, Inc. RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20040209831A1 (en) * 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
US20060019913A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US20080161256A1 (en) * 2001-05-18 2008-07-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) * 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050176666A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
US20050153914A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050159380A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
US20050233996A1 (en) * 2002-02-20 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20060211642A1 (en) * 2001-05-18 2006-09-21 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
US20050287128A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
US20050222066A1 (en) * 2001-05-18 2005-10-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050233344A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
US20050256068A1 (en) * 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20080188430A1 (en) * 2001-05-18 2008-08-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20050164968A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US20050159379A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
US20050182006A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
US20050136436A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
US20050014172A1 (en) * 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20040006035A1 (en) * 2001-05-29 2004-01-08 Dennis Macejak Nucleic acid mediated disruption of HIV fusogenic peptide interactions
US20050054598A1 (en) * 2002-02-20 2005-03-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20060142225A1 (en) * 2001-05-18 2006-06-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
US20050137155A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20060142226A1 (en) * 2001-05-18 2006-06-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
US20030130186A1 (en) * 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US20050130181A1 (en) * 2001-05-18 2005-06-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
US20050176664A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
US20050191638A1 (en) * 2002-02-20 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20050153915A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
US20050209180A1 (en) * 2001-05-18 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050079610A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050182007A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050124567A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
US20050164967A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050119212A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US20050080031A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
US20050124568A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
US20050164966A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
EP1390472A4 (en) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS
US20030140362A1 (en) * 2001-06-08 2003-07-24 Dennis Macejak In vivo models for screening inhibitors of hepatitis B virus
US7205399B1 (en) 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
AU2002313699A1 (en) * 2001-07-20 2003-03-03 Ribozyme Pharmacuticals, Inc. Enzymatic nucleic acid peptide conjugates
AU2002355571A1 (en) * 2001-08-09 2003-02-24 Archemix Corporation Nucleic acid sensor molecules and methods of using same
US8512953B2 (en) * 2001-09-24 2013-08-20 One Lambda Diagnostic probe detection system
WO2003052074A2 (en) * 2001-12-14 2003-06-26 Yale University Nucleic acid diagnostic reagents and methods for detecting nucleic acids, polynucleotides and oligonucleotides
AU2003208959A1 (en) * 2002-01-30 2003-09-02 Id Biomedical Corporation Methods for detecting vancomycin-resistant microorganisms and compositions therefor
US7071311B2 (en) * 2002-02-13 2006-07-04 Sirna Therapeutics, Inc. Antibodies having specificity for 2′-C-allyl nucleic acids
US20050042632A1 (en) * 2002-02-13 2005-02-24 Sirna Therapeutics, Inc. Antibodies having specificity for nucleic acids
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050096284A1 (en) * 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20050222064A1 (en) * 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050137153A1 (en) * 2002-02-20 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
WO2003106476A1 (en) * 2002-02-20 2003-12-24 Sirna Therapeutics, Inc Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
US20040018515A1 (en) * 2002-04-03 2004-01-29 Diener John L. Compositions selective for adenosine diphosphate and methods of using same
US20030228603A1 (en) * 2002-04-05 2003-12-11 Cload Sharon T. Compositions selective for caffeine or aspartame and methods of using same
US20030224435A1 (en) * 2002-05-16 2003-12-04 Scott Seiwert Detection of abused substances and their metabolites using nucleic acid sensor molecules
EP1513958B1 (en) 2002-06-14 2011-08-10 Gen-Probe Incorporated Compositions for detecting hepatitis b virus
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
AU2003247576A1 (en) * 2002-06-18 2003-12-31 Archemix Corp. Aptamer-toxin molecules and methods for using same
US20040110235A1 (en) * 2002-07-25 2004-06-10 David Epstein Regulated aptamer therapeutics
US20040137429A1 (en) * 2002-10-02 2004-07-15 David Epstein Therapeutic aptamers having binding specificity to gp41 of HIV
US8039443B2 (en) * 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US20040253243A1 (en) * 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20050037394A1 (en) * 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
US20040209353A1 (en) * 2002-12-12 2004-10-21 Chiron Corporation Biological sample storage device and method for biological sample contamination testing
US20040231231A1 (en) * 2002-12-20 2004-11-25 Cataldo Dominic A. Use of colloidal clays for sustained release of active ingredients
US20030232400A1 (en) * 2002-12-20 2003-12-18 Susan Radka Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
EP3222294A1 (en) 2003-04-30 2017-09-27 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
EP1717313A4 (en) * 2003-09-22 2007-11-14 Univ Kyoto NUCLEIC ACID ENZINE, NUCLEIC ACID CHIP, PROCESS FOR DETECTING TARGET NUCLEIC ACID, ACTIVE SCREENING METHOD, DEVICE FOR DETECTING TARGET NUCLEIC ACID AND GENDIAGNOSIS PROCEDURE
WO2005073405A2 (en) * 2004-01-29 2005-08-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Catalytic polynucleotide and its use for determination of analytes
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
DK1948822T3 (da) 2005-10-07 2011-10-17 Johnson & Johnson Res Pty Ltd Multikomponent-nukleinsyreenzymer og fremgangsmåder til deres anvendelse
GB0522310D0 (en) * 2005-11-01 2005-12-07 Solexa Ltd Methods of preparing libraries of template polynucleotides
GB0524069D0 (en) * 2005-11-25 2006-01-04 Solexa Ltd Preparation of templates for solid phase amplification
CA2645159A1 (en) * 2006-03-10 2008-06-26 Michael S. Urdea Multiplex protein fractionation
US20080009420A1 (en) * 2006-03-17 2008-01-10 Schroth Gary P Isothermal methods for creating clonal single molecule arrays
US7955443B2 (en) 2006-04-14 2011-06-07 Shin-Etsu Chemical Co., Ltd. Method for preparing rare earth permanent magnet material
EP2019857B1 (en) 2006-05-03 2016-09-28 The Regents of the University of Colorado, a body corporate Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
JP5248494B2 (ja) 2006-07-11 2013-07-31 ユニバーシティ・オブ・メディシン・アンド・デンティストリー・オブ・ニュージャージー タンパク質、それをコードする核酸および関連する使用方法
CN101600808B (zh) * 2006-10-06 2014-07-09 强生研究有限公司 分子开关及其使用方法
WO2008093098A2 (en) 2007-02-02 2008-08-07 Illumina Cambridge Limited Methods for indexing samples and sequencing multiple nucleotide templates
BRPI0809964A2 (pt) * 2007-04-05 2014-10-07 Johnson & Johnson Res Pty Ltd Método para detectar a presença um pelo menos um alvo, pelo menos dois alvos ou um apluralidade de alvos, método para a detecção de um primeiro facilitador de montagem usando uma cascata, uso de um par de ácidos nucléicos isolados, enzima mna ligase e seu uso, produto de enzima mna ligase, uso de pelo menos dois olingonucleotídeos cmo substratos
WO2010038042A1 (en) 2008-10-02 2010-04-08 Illumina Cambridge Ltd. Nucleic acid sample enrichment for sequencing applications
US20100305197A1 (en) * 2009-02-05 2010-12-02 Massachusetts Institute Of Technology Conditionally Active Ribozymes And Uses Thereof
US8182994B2 (en) 2009-09-15 2012-05-22 Illumina Cambridge Limited Centroid markers for image analysis of high denisty clusters in complex polynucleotide sequencing
MX348474B (es) * 2009-12-23 2017-06-14 Novartis Ag * Lipidos, composiciones de lipido, y metodos de uso de los mismos.
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
CN105164102B (zh) 2013-03-08 2017-12-15 诺华股份有限公司 用于传递活性成分的脂质和脂质组合物
ES2895651T3 (es) 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
JP6778175B2 (ja) 2014-07-16 2020-10-28 ノバルティス アーゲー 脂質ナノ粒子ホスト中に核酸を封入する方法
US10125092B2 (en) 2014-09-05 2018-11-13 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US10934549B2 (en) 2017-08-18 2021-03-02 University Of Iowa Research Foundation Nucleic acid aptamers
WO2020023741A1 (en) * 2018-07-25 2020-01-30 Ohio State Innovation Foundation Large scale production of rna particles
JP2023546175A (ja) 2020-10-14 2023-11-01 ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド 脂質ナノ粒子製造の方法及びそれに由来する組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775619A (en) * 1984-10-16 1988-10-04 Chiron Corporation Polynucleotide determination with selectable cleavage sites
WO1989005852A1 (en) * 1987-12-15 1989-06-29 Macphillamy Cummins & Gibson Ribozymes
JP3276955B2 (ja) * 1988-09-30 2002-04-22 ジーン−トラック・システムス Rnaの鋳型の末端に結合したプローブ構造およびその使用方法
NZ314629A (en) * 1991-01-17 2000-08-25 Gen Hospital Corp Use trans-splicing ribozymes to prepare medicaments for gene therapies

Also Published As

Publication number Publication date
WO1994013833A1 (en) 1994-06-23
JP2004000281A (ja) 2004-01-08
US5589332A (en) 1996-12-31
JPH08507202A (ja) 1996-08-06
AU5739694A (en) 1994-07-04
JP3595841B2 (ja) 2004-12-02
EP0681613B1 (en) 2002-05-08
DE69331911D1 (de) 2002-06-13
EP1195442A3 (en) 2002-07-31
DE69331911T2 (de) 2002-11-21
ATE217347T1 (de) 2002-05-15
EP0681613A1 (en) 1995-11-15
EP1195442A2 (en) 2002-04-10
AU675482B2 (en) 1997-02-06
EP0681613A4 (en) 1998-05-20

Similar Documents

Publication Publication Date Title
ES2176233T3 (es) Deteccion diagnostica amplificada con ribozimas.
Huang et al. Telomerase triggered DNA walker with a superhairpin structure for human telomerase activity sensing
Freeman et al. Probing protein kinase (CK2) and alkaline phosphatase with CdSe/ZnS quantum dots
Wang et al. Aptamer-based ATP assay using a luminescent light switching complex
Qian et al. Ultrasensitive electrochemical detection of DNA based on Zn2+ assistant DNA recycling followed with hybridization chain reaction dual amplification
NO900582L (no) Maalemetode.
EP1580269A4 (en) METHOD FOR GENERATING DETECTION PROCEDURE
AU2001233785A1 (en) Electrochemical sensor for determining blood clotting, corresponding system for measuring blood clotting and method for determining blood clotting
ATE394478T1 (de) Testverfahren mit reduziertem hintergrund
Ye et al. An intensive and glow-type chemiluminescence of luminol-embedded, guanosine-derived hydrogel
Xie et al. CRISPR-Cas12a coupled with DNA nanosheet-amplified fluorescence anisotropy for sensitive detection of biomolecules
CN109444102A (zh) 一种检测赭曲霉毒素a的荧光生物传感器及其制备方法和应用
CN107208140A (zh) 通过使用由靶材料调节的核酸聚合酶的活性用于检测和量化生物材料的方法
CN106520913A (zh) 基于酶切循环放大的石墨烯氧化物‑dna传感器的制备方法和在检测凝血酶上的应用
Lee et al. Folding of 8-17 deoxyribozyme studied by three-color alternating-laser excitation of single molecules
AR027726A1 (es) Sistemas reactivos para detectar la presencia de un cofactor reducido en una muestra y metodos para usarlos
Cheng et al. Peptide cleavage induced assembly enables highly sensitive electrochemiluminescence detection of protease activity
AU3414599A (en) Detection method
CN108398406B (zh) 一种检测尿嘧啶糖基化酶(udg)的生物传感器及其应用
Esimbekova et al. Disk-shaped immobilized multicomponent reagent for bioluminescent analyses: correlation between activity and composition
ES2083629T3 (es) Inmovilizacion de acidos nucleicos.
Wainberg et al. Investigation of the active center of trypsin using photochromic substrates
Qian et al. Assistant deoxyribonucleic acid recycling with Zn2+ and molecular beacon for electrochemical detection of deoxyribonucleic acid via target-triggered assembly of mutated DNAzyme
ATE335849T1 (de) Verfahren und nukleinsäuren zum nachweis von brauereirelevanten mikroorganismen
Wessel et al. Electron microscopy of DNA· helicase‐I complexes in the act of strand separation